Castle Biosciences (NASDAQ:CSTL) Expected to Post Quarterly Sales of $10.28 Million

Wall Street brokerages expect Castle Biosciences (NASDAQ:CSTL) to announce sales of $10.28 million for the current quarter, according to Zacks. Two analysts have made estimates for Castle Biosciences’ earnings. The highest sales estimate is $10.32 million and the lowest is $10.23 million. The firm is expected to issue its next earnings report on Tuesday, December 3rd.

According to Zacks, analysts expect that Castle Biosciences will report full year sales of $40.54 million for the current financial year, with estimates ranging from $40.31 million to $40.77 million. For the next year, analysts expect that the business will report sales of $49.93 million, with estimates ranging from $48.13 million to $51.73 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Castle Biosciences.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.54). The company had revenue of $10.74 million during the quarter, compared to analyst estimates of $7.06 million.

Several brokerages have recently weighed in on CSTL. Leerink Swann set a $33.00 price target on Castle Biosciences and gave the company a “buy” rating in a research report on Wednesday, September 4th. Svb Leerink began coverage on Castle Biosciences in a research report on Monday, August 19th. They set an “outperform” rating and a $28.00 price target on the stock. Robert W. Baird upped their price target on Castle Biosciences from $27.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, September 4th. Canaccord Genuity upped their price target on Castle Biosciences from $26.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Finally, BTIG Research upped their price target on Castle Biosciences to $32.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Five equities research analysts have rated the stock with a buy rating, Castle Biosciences has an average rating of “Buy” and an average target price of $31.60.

In other Castle Biosciences news, major shareholder Mgc Venture Partners 2013 Gp, acquired 312,500 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was bought at an average price of $16.00 per share, with a total value of $5,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director David S. Kabakoff acquired 62,500 shares of the business’s stock in a transaction dated Monday, July 29th. The shares were acquired at an average cost of $16.00 per share, with a total value of $1,000,000.00. The disclosure for this purchase can be found here.

Shares of CSTL traded up $0.06 during midday trading on Wednesday, hitting $23.00. 229,699 shares of the company traded hands, compared to its average volume of 130,979. The stock’s 50-day moving average is $22.79. Castle Biosciences has a one year low of $17.11 and a one year high of $28.50.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.

Featured Article: How does a dividend reinvestment plan work?

Get a free copy of the Zacks research report on Castle Biosciences (CSTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.